Published in Infect Immun on July 01, 1998
Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun (2004) 2.44
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol (2000) 1.48
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun (2001) 1.21
Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB. Infect Immun (1999) 1.17
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother (2013) 1.10
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect Immun (2005) 1.06
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol (2007) 1.05
Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect Immun (2004) 1.04
Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol (2006) 1.01
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol (2011) 0.99
A common gene pool for the Neisseria FetA antigen. Int J Med Microbiol (2008) 0.95
Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun (2009) 0.94
Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology (2011) 0.93
Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil. Trans R Soc Trop Med Hyg (2007) 0.90
Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect Immun (2003) 0.89
Variation and molecular evolution of HmbR, the Neisseria meningitidis haemoglobin receptor. Microbiology (2010) 0.89
Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic. J Clin Microbiol (2005) 0.89
Prospects for eradication of meningococcal disease. Arch Dis Child (2012) 0.86
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay. Clin Vaccine Immunol (2007) 0.85
Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol (2008) 0.85
Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B. Infect Immun (2011) 0.83
Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7. Clin Vaccine Immunol (2007) 0.81
A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect (2015) 0.80
Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity. Clin Vaccine Immunol (2009) 0.80
Seroepidemiological study after a long-distance industrial outbreak of legionnaires' disease. Clin Vaccine Immunol (2009) 0.80
Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infect Immun (2005) 0.78
FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression. PLoS One (2015) 0.77
Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2. Infect Immun (2001) 0.77
The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection. Genome Med (2010) 0.77
Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent. Clin Diagn Lab Immunol (1999) 0.76
An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. PLoS One (2015) 0.75
Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice. Infect Immun (2014) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis (1985) 6.62
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 5.63
Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A (1986) 5.39
Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol (1994) 4.95
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 3.32
Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol (1990) 2.58
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 2.52
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 2.44
Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol (1979) 2.23
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann (1991) 2.13
Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis (1998) 2.11
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 2.06
Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun (1994) 1.96
Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun (1986) 1.94
Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J Immunol Methods (1984) 1.82
The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res (1983) 1.75
Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann (1991) 1.68
Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun (1989) 1.59
Immunogenicity of meningococcal antigens as detected in patient sera. Infect Immun (1983) 1.58
Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis (1996) 1.55
Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect Immun (1994) 1.55
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine (1996) 1.54
Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981-1982. NIPH Ann (1983) 1.54
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun (1996) 1.54
The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis (1993) 1.42
Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis (1984) 1.41
Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol (1988) 1.34
Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J Med Microbiol (1993) 1.31
Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect Immun (1993) 1.30
Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine (1996) 1.27
A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb Pathog (1993) 1.25
Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J Immunol Methods (1988) 1.20
Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis. J Biol Chem (1993) 1.15
Meningococcal vaccines--present and future. Trans R Soc Trop Med Hyg (1991) 1.11
Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway. Clin Diagn Lab Immunol (1995) 1.10
Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect Immun (1994) 1.07
Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects. Infect Immun (1992) 1.01
Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease. APMIS (1989) 0.99
Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann (1991) 0.96
Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb Pathog (1997) 0.95
Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol (1995) 0.94
Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. J Infect Dis (1984) 0.94
Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. FEMS Immunol Med Microbiol (1997) 0.92
Antibody assisted protein refolding. Biotechnology (N Y) (1992) 0.92
The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann (1991) 0.90
A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease. Scand J Immunol (1993) 0.90
Low prevalence of complement deficiencies among patients with meningococcal disease in Norway. Scand J Immunol (1993) 0.89
Comparison of the class-1 outer membrane protein from B:15:P1.16 Neisseria meningitidis strains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway. Microb Pathog (1994) 0.86
Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH Ann (1991) 0.86
Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb Pathog (1995) 0.86
Antibody as an immunological probe for studying the refolding of bovine serum albumin. An immunochemical approach to the identification of possible nucleation sites. J Biol Chem (1978) 0.85
Antigens that are similar in apparent molecular weight to gonococcal outer membrane protein III. J Clin Microbiol (1987) 0.84
Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease. Microbiology (1996) 0.80
Several polymers enhance the sensitivity of the southwestern assay. Anal Biochem (1995) 0.77
Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection. FEMS Immunol Med Microbiol (1996) 0.77
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol (1994) 5.84
Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol (1986) 5.05
Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol (1994) 4.95
Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet (2001) 3.71
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet (1994) 3.16
Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol (1990) 2.58
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 2.44
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann (1991) 2.13
Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis (1998) 2.11
Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin Exp Immunol (1976) 2.08
Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986. J Infect Dis (1990) 1.96
Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis (1990) 1.91
The importance of blood volume cultured on detection of bacteraemia. Acta Pathol Microbiol Scand B (1981) 1.87
Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis (2005) 1.80
Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis. Antimicrob Agents Chemother (1993) 1.77
Some arguments on early hospital admission and treatment of suspected meningococcal disease cases. NIPH Ann (1990) 1.73
Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982. NIPH Ann (1983) 1.73
Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann (1991) 1.68
Mycobacterium leprae specific antibodies detected by radioimmunoassay. Scand J Immunol (1978) 1.61
Photoinhibition and Reactivation of Photosynthesis in the Cyanobacterium Anacystis nidulans. Plant Physiol (1985) 1.60
The effect of decentralisation on tuberculosis services in three states of Sudan. Int J Tuberc Lung Dis (2003) 1.59
Injectional anthrax in a heroin skin-popper. Lancet (2000) 1.58
Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis (1996) 1.55
Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981-1982. NIPH Ann (1983) 1.54
Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect (2000) 1.50
The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol (2009) 1.48
Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine (2003) 1.46
Evaluating an active case-finding strategy to identify smear-positive tuberculosis in rural Ethiopia. Int J Tuberc Lung Dis (2009) 1.44
The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis (1993) 1.42
Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun (1998) 1.42
Transmission of Neisseria meningitidis among asymptomatic military recruits and antibody analysis. Epidemiol Infect (1992) 1.39
Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand J Immunol (2007) 1.37
Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis (2002) 1.37
Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol (1988) 1.34
The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link? Clin Exp Immunol (2006) 1.33
In vitro lymphocyte stimulation in leprosy; simultaneous stimulation with Mycobacterium leprae antigens and phytohaemagglutinin. Clin Exp Immunol (1979) 1.31
Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. Int J Tuberc Lung Dis (2002) 1.30
Prevalence of pulmonary tuberculosis and associated risk factors in Eastern Ethiopian prisons. Int J Tuberc Lung Dis (2011) 1.27
A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb Pathog (1993) 1.25
Mycobacterial antigens in antibody responses of leprosy patients. Int J Lepr Other Mycobact Dis (1976) 1.23
Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol Med (2001) 1.23
Photon correlation spectroscopy of human IgG. J Protein Chem (1988) 1.21
Psychosocial determinants of sexual activity and condom use intention among youth in Addis Ababa, Ethiopia. Int J STD AIDS (2002) 1.21
Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect (1996) 1.20
Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen. J Clin Microbiol (1986) 1.19
Antigenic heterogeneity in patients with reactions in borderline leprosy. Br Med J (1975) 1.18
Characteristics of serogroup A Neisseria meningitidis responsible for an epidemic in Ethiopia, 1988-89. Scand J Infect Dis (1990) 1.18
Detection of the phosphorylcholine epitope in streptococci, Haemophilus and pathogenic Neisseriae by immunoblotting. Microb Pathog (1997) 1.17
Relation of grading of sputum smears with clinical features of tuberculosis patients in routine practice in Sudan. Int J Tuberc Lung Dis (2002) 1.17
A mouse model for slowly progressive primary tuberculosis. Scand J Immunol (1999) 1.16
Plasma factors in delayed-type hypersensitivity. Augmentation of lymphocyte responses in borderline leprosy reactions. Clin Exp Immunol (1976) 1.15
Outbreak of Shigella sonnei infection traced to imported iceberg lettuce. J Clin Microbiol (1995) 1.14
Evaluation of ten commercial heterophile antibody tests for infectious mononucleosis. Acta Pathol Microbiol Immunol Scand C (1985) 1.12
Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun (1995) 1.10
Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway. Clin Diagn Lab Immunol (1995) 1.10
Antibodies against BCG antigen 60 in mycobacterial infection. Br Med J (1977) 1.08
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol (2007) 1.05
Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants. Antimicrob Agents Chemother (2006) 1.04
The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine (1999) 1.04
Risk factors associated with typhoid fever in Son La province, northern Vietnam. Trans R Soc Trop Med Hyg (2005) 1.03
Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann (1991) 1.02
Severity of meningococcal disease: assessment by factors and scores and implications for patient management. Rev Infect Dis (1991) 1.02
Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol (2005) 1.02
Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine (2003) 1.02
Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine (1999) 1.01
Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine (2005) 1.01
Hodgkin's disease in patients with previous infectious mononucleosis. Int J Cancer (1979) 1.01
IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. APMIS (1990) 1.01
An evaluation of the diagnostic value of clinical and radiological manifestations in patients attending the addis ababa tuberculosis centre. Scand J Infect Dis (2001) 1.01
Cell mediated and humoral immunity in "reversal reactions". Int J Lepr Other Mycobact Dis (1976) 0.99
A comparison of human and murine monoclonal IgGs specific for the P1.7 PorA protein of Neisseria meningitidis. Mol Immunol (1994) 0.97
Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun (1999) 0.97
Emerging antibiotic resistance in Salmonella typhimurium in Norway. Epidemiol Infect (2000) 0.97
Bacterial shock due to transfusion with Yersinia enterocolitica infected blood. Scand J Infect Dis (1984) 0.97
Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. NIPH Ann (1991) 0.96
Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann (1991) 0.96